Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
anlotinib (1 trial)
neoantigen dna vaccine (1 trial)
tqb2450 (1 trial)
allogeneic natural killer cells (1 trial)
osimertinib (tagrisso) (1 trial)
ty-9591 (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Lung Neoplasms (Phase 2)
Trials (4 total)
Trial APIs (6 total)